FDA Drugs (New Approvals & NDA)Original article
Seema International - 716072 - 11/13/2025
RegulatoryNegative
AI Analysis
Summary
Seema International received an FDA enforcement action on 2025-11-13 related to CGMP violations and adulterated Active Pharmaceutical Ingredients. The action indicates regulatory non-compliance in manufacturing standards.
Outcome Details
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Importance:6/10
Sentiment:
-0.80
CGMP violationAPI adulterationRegulatory actionFDA enforcement
Read the original article
Published by FDA Drugs (New Approvals & NDA) on September 1, 2026 11:00 AM